Biocon Limited (BIOCON.NS)
| Previous Close | 309.25 |
| Open | 314.90 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 307.30 - 317.00 |
| 52 Week Range | 217.50 - 331.00 |
| Volume | |
| Avg. Volume | 8,699,927 |
| Market Cap | 370.651B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 36.26 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.50 (0.16%) |
| Ex-Dividend Date | Jul 04, 2024 |
| 1y Target Est | N/A |
- CNW Group
Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.
- CNW Group
Biocon Biologics Successfully Completes Integration of Viatris' Biosimilar Business in 31 Countries in Europe
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris' biosimilars business in 31 European countries has been successfully completed.
- CNW Group
Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars' Business In North America Ahead of Schedule
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Company has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023.
